QualityStocksNewsBreaks Archives

ThursdayJan 08, 2026 10:57 am

QualityStocksNewsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Demonstrates 100% Interception Success of DefendAir System Against Advanced Hostile Drones

ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company specializing in smart, autonomous solutions for manned and unmanned aerial systems, announced that its DefendAir Counter-Unmanned Aerial System has achieved 100% interception success in live field demonstrations against two of the most challenging hostile drone threats: FPV kamikaze attack drones and DJI FlyCart heavy-lift smuggling drones. Conducted under controlled real-world conditions, the demonstrations validated DefendAir’s patented, net-based, non-explosive interception technology, building on prior trials that also recorded perfect interception rates against fast-incoming multirotor threats and reinforcing the system’s applicability for military forces, border security and critical infrastructure protection. To view the full press release, visit https://ibn.fm/SEup5 About ParaZero Technologies ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense…

ThursdayJan 08, 2026 9:20 am

QualityStocksNewsBreaks – VolitionRx Limited (NYSE American: VNRX) Study Shows Nu.Q Vet Feline Test Accurately Detects Lymphoma in Cats

VolitionRx (NYSE American: VNRX), a multinational epigenetics company, announced results from a clinical study demonstrating high accuracy of its Nu.Q Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, meaning no false positives, the blood-based assay detected more than 80% of feline lymphomas, supporting development of what the company expects to be the world’s first simple and affordable liquid biopsy test for feline cancer. The company stated that feline cancer has historically been difficult to diagnose early, often requiring invasive biopsies or costly imaging after symptoms have progressed, and noted that…

ThursdayJan 08, 2026 9:10 am

QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Sets Feb. 21, 2026, Distribution Date for Previously Announced Warrant Dividend

Datavault AI (NASDAQ: DVLT), a leader in data monetization, credentialing and digital engagement technologies, announced that its board of directors has set Feb. 21, 2026, or such other date as determined by the board, as the distribution date for its previously announced dividend of warrants to purchase shares of common stock for eligible record equity holders. The previously announced record date remains Jan. 7, 2026, with the warrants to be distributed on the basis of one warrant for each 60 shares of common stock held, or shares underlying other Datavault AI equity securities, subject to applicable contractual terms. To view…

ThursdayJan 08, 2026 9:05 am

QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Expands IBM Collaboration to Deliver Enterprise AI at the Edge in New York and Philadelphia

Datavault AI (NASDAQ: DVLT), a leader in instant data monetization and enterprise digital twins, announced it will deliver enterprise-grade artificial intelligence performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform operated by Available Infrastructure. The deployment will utilize IBM watsonx AI products running within SanQtum AI’s zero-trust, micro edge data center network to enable cybersecure data storage and compute, real-time data scoring, tokenization, credentialing, and ultra-low-latency processing across two of the most data-dense metropolitan regions in the United States, supporting enterprise AI workloads without reliance on public cloud infrastructure.…

ThursdayJan 08, 2026 9:00 am

QualityStocksNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK

Lixte Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial evaluating its proprietary compound LB-100 in combination with GSK’s Dostarlimab for the treatment of ovarian clear cell cancer. The trial, initiated in January 2024 and led by Amir Jazaeri, MD, at MD Anderson, has added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University under the direction of Emily M. Hinchcliff, MD, MPH, and is expected to double enrollment to 42 patients following completion of its…

WednesdayJan 07, 2026 1:02 pm

QualityStocksNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Secures National Electronic Monitoring Contract in Western Europe, Expanding DV Solutions to 10th Country

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT and cybersecurity sectors, today announced it has secured a new national electronic monitoring contract in a Western European country through a partnership with a leading local service provider, marking the expansion of its proprietary domestic violence monitoring solutions to a tenth country worldwide and further strengthening its European footprint. The multi-year framework agreement, with a minimum term of three years, will support multiple national public safety agencies and programs, including domestic violence monitoring, GPS offender tracking and home detention, with the project expected to launch in the…

WednesdayJan 07, 2026 12:45 pm

QualityStocksNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS) Collaborates With Rokid to Enable Gesture Control for AI and AR Glasses

Wearable Devices (NASDAQ: WLDS) announced a collaboration with Rokid, a global pioneer in human-computer interaction and augmented reality, to enable natural, fast, and consistent gesture control for AI and AR glasses using the company’s Mudra Link neural wristband. Under the collaboration, Mudra Link and Rokid Glasses are compatible and ready for each other, featuring out-of-the-box pairing, pre-mapped gestures, and a shared setup flow, with joint marketing and consumer bundle opportunities planned for an initial rollout in the second quarter of 2026. The companies are also demonstrating the combined experience at CES 2026, highlighting a touch-free, wrist-based control approach designed to reduce friction in everyday interactions with smart glasses. announced…

WednesdayJan 07, 2026 12:21 pm

QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Collaborates With Riflessi to Deploy Immersive Retail Media Technologies

Datavault AI (NASDAQ: DVLT) announced a collaboration with Riflessi, a premium Fifth Avenue retail destination in New York City, to deploy the company’s DVHOLO(TM) holographic display platform and ADIO(R) spatial audio technology beginning in February 2026. The collaboration is designed to enable luxury fashion and lifestyle brands to sponsor immersive holographic and spatial audio experiences within high-value physical retail environments, supporting brand storytelling, pre-sale initiatives, and measurable consumer engagement while generating new revenue opportunities through Datavault AI’s data experience, valuation, and monetization framework. To view the full press release, visit https://ibn.fm/j6uUm About Datavault AI Inc. Datavault AI (NASDAQ: DVLT) is leading the way in AI experience, valuation, and monetization of assets in…

WednesdayJan 07, 2026 12:10 pm

QualityStocksNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Announces $4.3 Million Registered Direct Offering Priced at Market

Lixte Biotechnology Holdings (NASDAQ: LIXT) entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $4.3 million of Common Stock and pre-funded and investor warrants at a price of $4.09 per Common Unit, priced at the market under Nasdaq rules. The offering comprised 1,051,342 Common Units or Pre-Funded Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one Common Warrant exercisable at $3.96 per share, with the Common Warrants exercisable immediately and expiring 60 months from issuance. Gross proceeds totaled approximately $4.3 million, with net proceeds allocated for general corporate purposes and working capital. Spartan Capital Securities…

WednesdayJan 07, 2026 10:55 am

QualityStocksNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering

Estrella Immunopharma (NASDAQ: ESLA, ESLAW) announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor, generating aggregate gross proceeds of approximately $8.0 million. The offering included the issuance of 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, together with a concurrent private placement of common warrants to purchase up to 7,594,935 additional shares, with net proceeds expected to be used for general corporate purposes and working capital as the company advances its CD19 and CD22-targeted ARTEMIS T-cell therapy programs, including lead candidate EB103. Aegis Capital Corp. acted as exclusive placement agent for the…

Site Search

Company Search

Category: QualityStocksNewsBreaks